[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526691":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":31,"collaborators":26,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":26,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":26,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":26,"overallStatus":56,"whyStopped":26,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":26},{"fullName":5,"class":6},"Sichuan Cancer Hospital and Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"lidocaine group","EXPERIMENTAL","At the same time of induction of general anesthesia, an intravenous lidocaine bolus of 2mg\u002Fkg will be administered, followed by a continuous infusion of intravenous lidocaine at 2 mg\u002Fkg\u002Fh until the participate transfer out of postoperative anesthesia care unit.",[13],"Drug: intravenous lidocaine infusion",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","PLACEBO_COMPARATOR","The control group will receive the same volume of normal saline in bolus and continuous infusion.",[19],"Drug: Saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","intravenous lidocaine infusion","Lidocaine bolus of 2mg\u002Fkg after induction , and then continuous infusion with 2 mg\u002Fkg\u002Fh until the participate transfer out of postoperative anesthesia care unit.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Saline","Same volume of normal saline in bolus and continuous infusion as lidocaine group.",[15],{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Yihao Zhu","Dr.","100526691","intravenous-lidocaine-infusion-reduce-postoperative-pulmonary-complications-in-patients-undergoing-minimally-invasive-esophagectomy-100526691",false,"NCT06138041","Intravenous Lidocaine Infusion Reduce Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy","Effect of Intravenous Lidocaine Infusion on Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy: a Double-center, Double-blind, Randomized Controlled Trial","Inclusion Criteria:\n\nPatients between 18 and 85 years of age with a recent schedule for MIE are screened for this study. Patients who show clear consciousness and ASA status I - III will be included as eligible participants.\n\nExclusion Criteria:\n\nThe exclusion criteria are as follows: patients with severe psychiatric disorders, such as schizophrenia, depression, dementia, etc.; severe hepatic insufficiency (concentration of glutamic oxaloacetic transaminase, glutamic pyruvic transaminase or bilirubin ≥2.5 times the upper limit of normal); renal impairment (creatinine clearance \\\u003C60 mL\u002Fmin); allergy to amide local anesthetics; history of seizures; presence of II\u002FIII atrioventricular block; patients with severe sinus bradycardia or sick sinus syndrome; patients with Adams-Stokes syndrome or pre-excitation syndrome; intracardiac block (e.g. complete bundle branch block, atrioventricular block); serum potassium ion concentration below 2.5 or above 5.0 mmol\u002FL; PH\\>7.55 or PH\\\u003C7.2. Patients will be discontinued if any of the following situations occur: the patient has an allergic reaction, severe cardiovascular events that cannot be managed with symptomatic treatment, and the patient is unwilling to continue the study.","ALL","18 Years","85 Years",{"count":46,"type":47},770,"ESTIMATED","INTERVENTIONAL",[50],"NA","The goal of this double-center, double-blind, randomized controlled clinical trial is to compare the effect of intravenous lidocaine infusion on postoperative pulmonary complications in patients undergoing minimally invasive esophagectomy. The main question it aims to answer are whether intravenous lidocaine reduce postoperative pulmonary complications in patients undergoing minimally invasive esophagectomy. Participants will be given intravenous lidocaine infusion in lidocaine group or placebo in control group.",[53,54,55],"Postoperative Pneumonia","Postoperative Pulmonary Atelectasis","Postoperative Pulmonary Edema","NOT_YET_RECRUITING","2024-10-20",{"date":59,"type":60},"2024-10-22","ACTUAL",{"date":62,"type":47},"2025-02-01",{"date":64,"type":47},"2025-08-30",{"name":5,"class":6}]